Publications by authors named "M Tesselaar"
Sarcopenia is a muscle disease that occur across a lifetime. It is commonly described in the aging population but can occur earlier in life in patients with cancer. Previous studies demonstrated sarcopenia is highly prevalent in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
View Article and Find Full Text PDFArticle Synopsis
- Diagnosing rare cancers is tough and often takes a long time, according to a study that examined the experiences of 1541 patients in The Netherlands from GP visits to final diagnoses.
- Most patients (76.0%) started with a GP consultation, and while 76.3% were referred to a hospital within three months, 32.1% received incorrect diagnoses that led to unnecessary treatments.
- The study found significant differences in diagnosis timelines between solid and non-solid tumors, with patients experiencing varying waits; improving research on symptoms and clinical networks could help reduce these delays.
This study provides a comprehensive review of the literature on climate risk insurance modeling to identify lessons learned and knowledge gaps to be addressed by future research. These models are increasingly relevant due to the rising losses attributable to climate change. Insurance models estimate risk for different perils and simulate risk-related parameters for insurance schemes, such as premiums and deductibles.
View Article and Find Full Text PDFPurpose Of Review: To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments.
Recent Findings: Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e.
Patients with neuroendocrine tumours located in the gastroenteropancreatic tract (GEP-NETs) and treatment with somatostatin analogues (SSA's) are at risk of malnutrition which has been reported previously evaluating weight loss or body mass index (BMI) only. The global leadership into malnutrition (GLIM) criteria include weight loss, BMI, and sarcopenia, for diagnosing malnutrition. These GLIM criteria have not been assessed in patients with GEP-NETs on SSA.
View Article and Find Full Text PDF